![](/img/cover-not-exists.png)
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
Blackwell, K., Semiglazov, V., Krasnozhon, D., Davidenko, I., Nelyubina, L., Nakov, R., Stiegler, G., Singh, P., Schwebig, A., Kramer, S., Harbeck, N.Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv281
Date:
June, 2015
File:
PDF, 359 KB
english, 2015